CD8A and triple-negative breast carcinoma: More specifically, the presence of CD8+ T cells is associated with improved long-term survival in both HER2+ and triple-negative breast cancers [6], and there is evidence that chemotherapeutic agents promote CD8+ T cell-mediated immunogenic tumor cell killing [7].